Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus HYTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus HYTRIN.
FLOMAX vs HYTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker